If future studies continue validating these results, the company could emerge as a differentiated participant in one of the largest and fastest-growing therapeutic categories in modern healthcare
Why monitoring matters more after 50 on GLP-1 medications One of the biggest challenges with GLP-1 treatment is that many programs rely on periodic check-ins rather than continuous monitoring
The Semaglutide cohort compared to the non-GLP-1RA anti-obesity medications cohort was older, had a lower prevalence of adverse socioeconomic determinants of health, mental disorders, and substance use disorders, and a higher prevalence of morbid obesity, T2D and obesity-associated comorbidities
These options minimize empty calories while supporting steady energy levels
They will be like the fat lazy glutton in the TV ad (I thought direct-to-patient advertising was illegal in UK??) who just wants to be entitled to get injections so that she can go on eating constantly, like she does in the TV video
Racial Disparities in Access One of the most concerning aspects of the GLP-1 market is the racial disparities in access